Abstract
The metabolic syndrome represents a clustering of risk factors that has been shown to predict adverse cardiovascular outcomes. Although the precise mechanisms contributing to the cardiometabolic syndrome (CMS) remain poorly defined, accumulating evidence identifies two intersecting candidate pathways responsible for inflammation and energy homeostasis in the pathophysiology that underlie cardiometabolic traits. Although currently no pharmacologic interventions specifically target CMS, future drug development efforts should attempt to capitalize on molecular nodes at the intersections of these pathways in the CMS.
Keywords: Metabolic syndrome, cardiometabolic syndrome, substrate metabolism, inflammation, obesity, insulin resistance, hypertension, dyslipidemia
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title: Molecular Determinants of the Cardiometabolic Phenotype
Volume: 10 Issue: 2
Author(s): Lisa de las Fuentes, Giovanni de Simone, Donna K. Arnett and Victor G. Davila-Roman
Affiliation:
Keywords: Metabolic syndrome, cardiometabolic syndrome, substrate metabolism, inflammation, obesity, insulin resistance, hypertension, dyslipidemia
Abstract: The metabolic syndrome represents a clustering of risk factors that has been shown to predict adverse cardiovascular outcomes. Although the precise mechanisms contributing to the cardiometabolic syndrome (CMS) remain poorly defined, accumulating evidence identifies two intersecting candidate pathways responsible for inflammation and energy homeostasis in the pathophysiology that underlie cardiometabolic traits. Although currently no pharmacologic interventions specifically target CMS, future drug development efforts should attempt to capitalize on molecular nodes at the intersections of these pathways in the CMS.
Export Options
About this article
Cite this article as:
de las Fuentes Lisa, de Simone Giovanni, K. Arnett Donna and G. Davila-Roman Victor, Molecular Determinants of the Cardiometabolic Phenotype, Endocrine, Metabolic & Immune Disorders - Drug Targets 2010; 10 (2) . https://dx.doi.org/10.2174/187153010791213119
DOI https://dx.doi.org/10.2174/187153010791213119 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Revised Genetic Classification of Limb Girdle Muscular Dystrophies
Current Molecular Medicine Refined Echocardiographic Assessment and Contemporary Medical Treatment of Obstructive Hypertrophic Cardiomyopathy
Cardiovascular & Hematological Disorders-Drug Targets Berberine: New Insights from Pharmacological Aspects to Clinical Evidences in the Management of Metabolic Disorders
Current Medicinal Chemistry Beyond Ejection Fraction: Novel Clinical Approaches Towards Sudden Cardiac Death Risk Stratification in Patients with Dilated Cardiomyopathy
Current Cardiology Reviews Lipotoxicity Disrupts Erythrocyte Function: A Perspective
Cardiovascular & Hematological Disorders-Drug Targets Myocardial Expression of TNF-α, IL-1β, IL-6, IL-8, IL-10 and MCP-1 After a Single MDMA Dose Administered in a Rat Model
Current Pharmaceutical Biotechnology Preclinical Development of New Therapy for Glycogen Storage Diseases
Current Gene Therapy Current Status in Iron Chelation in Hemoglobinopathies
Current Molecular Medicine Prognostic Implications of Genetics in Cardiovascular Disease
Current Pharmacogenomics Heart Failure in Diabetes Mellitus: An Updated Review
Current Pharmaceutical Design Bioengineering RNA Silencing Across the Life Kingdoms
Recent Patents on Biotechnology The Role of PPARs in Pathological Cardiac Hypertrophy and Heart Failure
Current Pharmaceutical Design Beta-Blocker Therapy for Septic Cardiac Shock: Fiction Or Realism?
Current Drug Therapy Nitrogen Biobank for Cardiovascular Research
Current Cardiology Reviews Nanocarriers in the Delivery of Hydroxychloroquine to the Respiratory System: An Alternative to COVID-19
Current Drug Delivery Pegylated Liposomal Doxorubicin in Salvage Chemotherapy for Multiple Myeloma Patients
Current Cancer Therapy Reviews New Cell Therapy Using Bone Marrow-Derived Stem Cells/Endothelial Progenitor Cells to Accelerate Neovascularization in Healing of Experimental Ulcerative Colitis
Current Pharmaceutical Design Patent Selections:
Recent Patents on Inflammation & Allergy Drug Discovery Neurodevelopmental Delay and Intellectual Disability in Pediatric Heart Transplant
Current Psychiatry Reviews Prevention of Atherosclerosis by Interference with the Vascular Nitric Oxide System
Current Pharmaceutical Design